CSF1 Therapy for Chronic Liver Disease
Sector: Education • Location: Australia
Source: GrantConnect
Chronic liver disease (CLD) is a major health burden. The defining feature of CLD is scarring of the liver (fibrosis), which can lead to loss of liver function and death. Macrophages are cells of the immune system that play critical roles in both fibrosis progression and fibrosis resolution. We have identified a growth factor that may switch pro-fibrotic macrophages to anti-fibrotic macrophages. I
- Status
- Prospective
- Sector
- Education, Hospital, Government
- Location
- Australia
- Updated
- 19 Nov 2026
- Source
- GrantConnect
ConstructChat
Ask ConstructChat about CSF1 Therapy for Chronic Liver Disease
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | grant award |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Chronic liver disease (CLD) is a major health burden. The defining feature of CLD is scarring of the liver (fibrosis), which can lead to loss of liver function and death. Macrophages are cells of the immune system that play critical roles in both fibrosis progression and fibrosis resolution. We have identified a growth factor that may switch pro-fibrotic macrophages to anti-fibrotic macrophages. In this Project we will investigate the therapeutic potential of this growth factor in CLD. |
Original sector | Medical Research |
Budget |
Location
Country | Australia |
Source
Source | GrantConnect |
URL |
More Details
Record type | Project |
Sector | Education, Hospital, Government |
Article published date | 2024-12-16 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
